Xeloda Adjuvant Colon Cancer sNDA Supports New Standard Of Care, Roche Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral Xeloda could replace standard I.V. 5-FU/LV regimen based on X-ACT trial, which showed equivalence in disease-free survival and safety benefits, Roche says. Supplemental NDA for first-line post-surgical treatment of colon cancer has an expected user fee date of June 2005.